Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · Real-Time Price · USD

0.3053

+0.0193 (6.75%)

At close: Aug 13, 2026, 4:00 PM EDT

0.3054

+0.0001 (0.03%)

After-hours: Aug 13, 2026, 7:59 PM EDT

Vivos Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2.11	2.03	6.26	1.64	3.52	24.03
Cash & Short-Term Investments	2.11	2.03	6.26	1.64	3.52	24.03
Cash Growth	-9.91%	-67.59%	281.01%	-53.31%	-85.36%	31.99%
Accounts Receivable	1.77	1.58	0.43	0.2	0.46	1.2
Total Trade Receivables	1.77	1.58	0.43	0.2	0.46	1.2
Other Current Assets	0.94	0.77	0.78	0.62	1.45	2.09
Total Current Assets	4.82	4.38	7.47	2.46	5.42	27.32
Net Property, Plant & Equipment	7.56	7.92	4.34	4.7	4.78	2.83
Other Intangible Assets	3.84	4.05	0.41	0.42	0.31	0.34
Goodwill	8.57	8.57	2.84	2.84	2.84	2.84
Other Long-Term Assets	0.25	0.23	0.22	0.31	0.37	0.36
Total Assets	25.04	25.15	15.28	10.73	13.72	33.69

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2	1.68	1.1	2.15	1.41	0.92
Accrued Expenses	6.11	5.99	2.23	2.33	1.91	2.85
Current Portion of Long-Term Debt	7.3	8.35	-	-	-	1.27
Current Portion of Leases	0.8	0.73	0.48	0.47	0.42	-
Unearned Revenue	0.5	0.48	0.9	2.14	2.93	2.4
Other Current Liabilities	1.23	0.85	0.27	0.2	0.15	0.07
Total Current Liabilities	17.94	18.08	4.98	7.29	6.81	7.51
Long-Term Debt	0.42	0.47	-	-	-	-
Long-Term Leases	3.75	3.95	1.04	1.52	1.99	-
Other Long-Term Liabilities	4.2	4.2	1.32	1.51	0.11	0.64
Total Long-Term Liabilities	8.37	8.63	2.35	3.03	2.11	0.64
Total Liabilities	26.31	26.7	7.33	10.32	8.92	8.15

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	-	-	-	-	-	0
Additional Paid-in Capital	131.9	123.87	112.14	93.46	84.27	81.16
Retained Earnings	-	-	-	-93.05	-79.47	-55.62
Total Common Shareholders' Equity	131.9	123.87	112.14	0.41	4.8	25.54
Minority Interest	0.13	0.06	-	-	-	-
Shareholders' Equity	-1.27	-1.55	7.95	0.41	4.8	25.54
Total Liabilities & Equity	25.04	25.15	15.28	10.73	13.72	33.69

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	12.27	13.5	1.51	2	2.41	1.27
Net Cash (Debt)	-10.16	-11.47	4.75	-0.35	1.11	22.77
Net Cash Growth	-	-	-	-	-95.14%	34.58%
Net Cash Per Share	-0.86	-1.12	0.95	-0.29	1.20	26.80
Book Value	131.9	123.87	112.14	0.41	4.8	25.54
Book Value Per Share	11.20	12.06	22.34	0.34	5.22	30.07
Tangible Book Value	119.49	111.25	108.89	-2.85	1.65	22.36
Tangible Book Value Per Share	10.15	10.83	21.69	-2.34	1.79	26.32

SEC Filings: 10-K · 10-Q